🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to researchers.

An International Public Health Issue

The sexually transmitted infection are increasing worldwide, with figures suggesting over 82 million infections each year. Particularly high rates are seen in the African continent and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This milestone marks a major breakthrough in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Outcomes and Worldwide Availability

According to data published in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves a dual-drug approach. The research included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors on the front lines have expressed optimism. Access to a easy-to-administer therapy such as this is seen as a "critical tool" for managing the epidemic. This is considered crucial to reduce the burden of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea globally.